Verdad Advisers’s Maze Therapeutics MAZE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$349K Buy
12,829
+211
+2% +$5.86K 0.37% 102
2026
Q2
$377K Buy
+12,618
New +$331K 0.36% 100

Other funds holding MAZE

Verdad Advisers's MAZE Position: Q3 2026 in Review

Verdad Advisers increased its Maze Therapeutics (MAZE) stake by 1.7% in Q3 2026, buying an estimated $5.86K and bringing the position to 12,829 shares worth $349K. The position accounts for 0.37% of the portfolio, ranked #102.

Verdad Advisers first reported a position in MAZE in Q2 2026 and has held it in 2 quarters since. The position peaked at $377K in Q2 2026. 158 funds tracked by Wall St. Rank hold MAZE as of Q3 2026.

  • Verdad Advisers held 12,829 shares of Maze Therapeutics worth $349K as of Q3 2026.
  • Verdad Advisers bought 211 Maze Therapeutics shares in Q3 2026, an estimated $5.86K.
  • Maze Therapeutics made up 0.37% of Verdad Advisers's portfolio in Q3 2026, its #102 holding.
  • Verdad Advisers first reported a position in Maze Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Verdad Advisers's Maze Therapeutics position peaked at $377K in Q2 2026.
  • 158 funds tracked by Wall St. Rank held Maze Therapeutics as of Q3 2026.

Based on Verdad Advisers's 13F filing for Q3 2026, filed 16 Nov 2026.